CoChat
Sign Up
Cited by 42Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in CancerHeterocyclic Compound Synthesis and Bioactivity

The DOI matches its Crossref record; its reference list is not available.

Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)

Ban, Hyun Seung, Uto, Yoshikazu, Nakamura, Hiroyuki·2011·Expert Opinion on Therapeutic Patents
DOI 10.1517/13543776.2011.547477
Open this paper in CoChat — free account

Abstract

Introduction Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor consisting of α and β subunits that regulates the expression of angiogenic factors, including VEGF, which are involved in angiogenesis, invasion/metastasis, glucose uptake and cell survival during cancer development. Areas covered This review summarizes the information about patented HIF inhibitors over the last 7 years (2004 - 2010). The reader will gain an outline of the structure and biological activity of recently developed HIF inhibitors. Expert opinion Inhibition of HIF is an attractive therapeutic target for tumor angiogenesis and, until now, various HIF inhibitors have been discovered and evaluated. It is expected that development of more potent and selective HIF inhibitors will provide an effective treatment of cancer and other HIF-related diseases, including inflammation and cardiovascular disorder. As VEGF plays an important role in angiogenesis during tumor growth and ischemic diseases, the inhibition of VEGF-induced HIF is an attractive approach for the suppression of hypoxia-mediated pathological angiogenesis. HIF inhibitors may not only have cytostatic antitumor effects with fewer side effects, but also synergetic effects combined with radiotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1517/13543776.2011.547477

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 87 · Cited by 42

Research works printed but not linked: 60

  1. 10.1128/MCB.12.12.5447 · DOI · Paper page
  2. Shweiki D, 1992, Nature, 359, 843, 10.1038/359843a0 · DOI · Paper page
  3. Wang GL, 1995, Proc Natl Acad Sci USA, 92, 5510, 10.1073/pnas.92.12.5510 · DOI · Paper page
  4. Iwai K, 1999, Proc Natl Acad Sci USA, 96, 12436, 10.1073/pnas.96.22.12436 · DOI · Paper page
  5. Maxwell PH, 1999, Nature, 399, 271, 10.1038/20459 · DOI · Paper page
  6. 10.1038/35017054 · DOI · Paper page
  7. Yu F, 2001, Proc Natl Acad Sci USA, 98, 9630, 10.1073/pnas.181341498 · DOI · Paper page
  8. Cockman ME, 2000, J Biol Chem, 275, 25733, 10.1074/jbc.M002740200 · DOI
  9. Kallio PJ, 1999, J Biol Chem, 274, 6519, 10.1074/jbc.274.10.6519 · DOI
  10. Berra E, 2001, FEBS Lett, 491, 85, 10.1016/S0014-5793(01)02159-7 · DOI
  11. Hewitson KS, 2002, J Biol Chem, 16, 1466
  12. Jaakkola P, 2001, Science, 292, 468, 10.1126/science.1059796 · DOI · Paper page
  13. Zhong H, 1999, Cancer Res, 59, 5830
  14. Folkman J, 2007, Nat Rev Drug Discov, 6, 273, 10.1038/nrd2115 · DOI
  15. Bertout JA, 2008, Nat Rev Cancer, 8, 967, 10.1038/nrc2540 · DOI · Paper page
  16. Semenza GL, 2003, Nat Rev Cancer, 3, 721, 10.1038/nrc1187 · DOI · Paper page
  17. Kirkpatrick DL, 1998, Biochem Pharmacol, 55, 987, 10.1016/S0006-2952(97)00597-2 · DOI
  18. Welsh SJ, 2003, Mol Cancer Ther, 2, 235
  19. Ramanathan RK, 2007, Clin Cancer Res, 13, 2109, 10.1158/1078-0432.CCR-06-2250 · DOI
  20. Welsh S, 2004, Mol Cancer Ther, 3, 233, 10.4161/cbt.3.2.775 · DOI
  21. Tibes R, 2010, J Clin Oncol, 28, 3076, 10.1200/JCO.2009.27.9414 · DOI
  22. Teng CM, 1997, Eur J Pharmacol, 320, 161, 10.1016/S0014-2999(96)00911-9 · DOI
  23. Galle J, 1999, Br J Pharmacol, 127, 195, 10.1038/sj.bjp.0702495 · DOI
  24. Chun YS, 2001, Biochem Pharmacol, 61, 947, 10.1016/S0006-2952(01)00564-0 · DOI · Paper page
  25. Nicolaou KC, 2000, J Am Chem Soc, 122, 9939, 10.1021/ja002033k · DOI
  26. Nicolaou KC, 2000, J Am Chem Soc, 122, 9954, 10.1021/ja002034c · DOI
  27. Nicolaou KC, 2000, J Am Chem Soc, 122, 9968, 10.1021/ja0020355 · DOI
  28. Lee HH, 1992, J Med Chem, 35, 258, 10.1021/jm00080a009 · DOI
  29. Creighton-Gutteridge M, 2007, Clin Cancer Res, 13, 1010, 10.1158/1078-0432.CCR-06-2301 · DOI
  30. Yewalkar N, 2010, Bioorg Med Chem Lett, 20, 6426, 10.1016/j.bmcl.2010.09.083 · DOI
  31. Noguchi T, 2005, Bioorg Med Chem Lett, 15, 5509, 10.1016/j.bmcl.2005.08.086 · DOI
  32. Lee K, 2010, Biochem Pharmacol, 80, 982, 10.1016/j.bcp.2010.06.018 · DOI · Paper page
  33. Lee K, 2007, J Med Chem, 50, 1675, 10.1021/jm0610292 · DOI
  34. Won MS, 2009, Biochem Biophys Res Commun, 385, 16, 10.1016/j.bbrc.2009.05.022 · DOI
  35. Shimizu K, 2010, Bioorg Med Chem Lett, 20, 1453, 10.1016/j.bmcl.2009.12.037 · DOI
  36. Ban HS, 2010, J Am Chem Soc, 132, 11870, 10.1021/ja104739t · DOI
  37. Moreno-Manzano V, 2010, J Biol Chem, 285, 1333, 10.1074/jbc.M109.008326 · DOI
  38. 10.4161/cc.9.14.12250 · DOI
  39. Duellman SJ, 2010, Biochem Pharmacol, 80, 819, 10.1016/j.bcp.2010.05.024 · DOI
  40. Whitesell L, 1994, Proc Natl Acad Sci USA, 91, 8324, 10.1073/pnas.91.18.8324 · DOI · Paper page
  41. Kaur G, 2004, Clin Cancer Res, 10, 4813, 10.1158/1078-0432.CCR-03-0795 · DOI
  42. Mabjeesh NJ, 2002, Cancer Res, 62, 2478
  43. Liu YV, 2007, Mol Cell, 25, 207, 10.1016/j.molcel.2007.01.001 · DOI
  44. Kamal A, 2003, Nature, 425, 407, 10.1038/nature01913 · DOI
  45. Ronnen EA, 2006, Invest New Drugs, 24, 543, 10.1007/s10637-006-9208-z · DOI
  46. Richardson PG, 2010, Br J Haematology, 150, 438, 10.1111/j.1365-2141.2010.08265.x · DOI
  47. Vaishampayan UN, 2010, Clin Cancer Res, 16, 3795, 10.1158/1078-0432.CCR-10-0503 · DOI
  48. Isham CR, 2007, Blood, 109, 2579, 10.1182/blood-2006-07-027326 · DOI
  49. Rao KV, 1987, Pharmacol Res Commun, 19, 629, 10.1016/0031-6989(87)90117-2 · DOI
  50. Hwang BY, 2003, Phytochemistry, 64, 765, 10.1016/S0031-9422(03)00391-1 · DOI
  51. Lee WS, 2004, Bioorg Med Chem Lett, 14, 3109, 10.1016/j.bmcl.2004.04.023 · DOI
  52. Lee JH, 2003, Biochem Pharmacol, 66, 1925, 10.1016/S0006-2952(03)00553-7 · DOI
  53. Le Cras TD, 2010, Am J Pathology, 176, 679, 10.2353/ajpath.2010.090123 · DOI
  54. Patnaik A, 2009, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.2564 · DOI · Paper page
  55. Wang GL, 1995, J Biol Chem, 270, 1230, 10.1074/jbc.270.3.1230 · DOI
  56. Yan L, 2010, Expert Opin Ther Patients, 20, 1219, 10.1517/13543776.2010.510836 · DOI
  57. 10.4161/cbt.4.10.2195 · DOI
  58. Liu P, 2009, Nat Rev Drug Discov, 8, 627, 10.1038/nrd2926 · DOI
  59. Aebersold DM, 2001, Cancer Res, 61, 2911
  60. Schwartz DL, 2009, Mol Cancer Ther, 8, 947, 10.1158/1535-7163.MCT-08-0981 · DOI

Metadata

Authors
Ban, H. S., Uto, Y., & Nakamura, H.
Affiliations
Gakushuin University (JP)
ORCID
Venue
Expert Opinion on Therapeutic Patents
Publisher
Informa UK Limited
Published
2011-01-06
Volume
21
Issue
2
Pages
131-146
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
DOI
10.1517/13543776.2011.547477
OpenAlex
W2037524661
Cited by
42
References
87
Citations by year
2024: 1 · 2022: 2 · 2021: 1 · 2019: 5 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 3 · 2013: 5 · 2012: 8
FWCI
2.27
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Patents (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (22790113, 23390013)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
hypoxia-inducible factor, vascular endothelial growth factor, tumor angiogenesis, anticancer drug development, hypoxia, inflammation, cardiovascular disease, combined radiotherapy, metastasis
MeSH terms
Animals, Antineoplastic Agents, Disulfides, Estradiol, Furans, Humans, Imidazoles, Indazoles, Mustard Compounds, Patents as Topic, Phenylpropionates, Piperazines, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review